GlassScriptPhysician profile
Murlidhar A Amin
NPI 1477550697
$186,434.20
in general payments reported to CMS, 2019-2025
25 companies · $31K in 2025
The $31K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $14K · 2021: $34K · 2022: $36K · 2023: $32K · 2024: $39K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $90K · Consulting Fee: $11K · Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $90,000.00 |
| Consulting Fee | $10,750.00 |
| Food and Beverage | $1,000.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $146,860.69 | 2020-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $37,859.80 | 2019-2025 | Accent, Gallant, Allure |
| Boston Scientific Corporation | $351.44 | 2019-2024 | Ranger, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Merck Sharp & Dohme LLC | $250.99 | 2021-2025 | Verquvo |
| Medtronic, INC. | $145.42 | 2022-2025 | Venaseal, Corevalve Evolut R |
| Pfizer INC. | $141.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $137.10 | 2023-2025 | |
| Amgen INC. | $123.78 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $123.58 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $107.26 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.75 | 2022-2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $33.92 | 2020-2021 | |
| Cardiva Medical, INC. | $31.45 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Shockwave Medical, INC | $24.21 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $23.09 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $22.31 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $21.19 | 2023 | Inpefa |
| Novo Nordisk INC | $20.81 | 2023 | Ozempic |
| Cordis US Corp. | $17.99 | 2024 | Mynx Control |
| Medicomp INC | $17.03 | 2023 | Telepatch Cardiac Monitor |
| Scpharmaceuticals INC. | $16.76 | 2025 | |
| Convatec INC. | $13.18 | 2023 | |
| Amarin Pharma, INC. | $12.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murlidhar Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.